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Effect of colloid volume expansion on glomerular barrier size—selectiv-
ity in humans. Colloid volume expansion magnifies proteinuria in
subjects with the nephrotic syndrome. To elucidate this phenomenon,
we performed differential solute clearances prior to and following
infusion of hyperoncotic albumin in 21 ncphrotic subjects and seven
healthy controls. Urinary excretion rate and fractional clearance of
albumin (radius = 36 A) and immunoglobulin G (radius = 55 A)
increased significantly in nephrotic subjects. However, urinary albumin
excretion rate was unchanged in controls. The fractional clearances of
dextrans of broad size distribution (radii = 28 to 58 A) were markedly
altered in both groups following albumin infusion. A heteroporous
model which depicts the major portion of the glomerular capillary wall
as an isoporous membrane (pore radius —55 A) and the minor portion as
a non-discriminatory shunt, revealed the latter to be much more
prominent in nephrotic subjects than in controls, and to be enlarged
further following albumin infusion. By contrast no increase in pore size
of the non-shunt pathway occurred in either group. We infer that
enhancement of a pre-existing defect of glomerular size—selectivity in
nephrotic subjects accounts, in large part, for exaggerated proteinuria
in the colloid volume—expanded state. Increases in glomerular perfusion
rate and pressure associated with plasma hypervolemia may mediate
this alteration in glomerular membrane—pore structure.
Colloid volume expansion has long been known to magnify
proteinuria in patients with the nephrotic syndrome [1—3]. The
mechanism of increased urinary protein leakage in these earlier
studies has not, however, been determined. Micropuncture
studies in the normal rat [4—6] and the dog [7] have revealed that
hyperoncotic albumin infusion elevates the prevailing oncotic
pressure along the entire length of glomerular capillaries. This is
accompanied by a decline in cortical microvascular resistances,
with the result that glomerular perfusion rate and hydraulic
pressure increase in parallel with the oncotic pressure. It is
conceivable that these or other biophysical influences associ-
ated with acute colloid infusion might alter the intrinsic prop-
erties of the glomerular filtration barrier, thereby facilitating the
passage of circulating proteins into Bowman's space. On the
other hand, hyperoncotic albumin infusion in the rat and dog
has also been shown to increase plasma albumin concentration,
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and the attendant volume expansion elevates the glomerular
filtration rate [3—7] thereby making it possible for the filtered
protein load to increase without an accompanying change in
filtration barrier charge or size—selectivity. Under these circum-
stances, constant or declining fractional tubular reabsorption of
filtered protein may account for enhancement of nephrotic
range proteinuria during colloid volume expansion [8].
To distinguish these possibilities, we studied patients with the
nephrotic syndrome before and during colloid volume expan-
sion, comparing clearances of proteins to those of neutral
dextrans of broad size distribution. Because the test dextran
preparation was uncharged, and because dextran is excreted
solely by glomerular filtration and neither secreted into nor
reabsorbed from the tubule lumen [9, 10], any changes in its
urinary clearance relative to that of freely—permeable inulin
should reflect uniquely alterations in the size—selective proper-
ties of the glomerular filter. By applying the observed dextran
filtration data to a theoretical model of solute transport that
accurately represents the nephrotic glomerular capillary wall as
a heteroporous membrane [lii, we have identified an alteration
in glomerular membrane—pore structure of the nephrotic subject
during colloid volume expansion.
Methods
Patient population
Twenty—one patients with nephrotic range proteinuria (>
3.5gl24 hr) comprised the experimental population. Renal bi-
opsy revealed a variety of underlying glomerular diseases
including proliferative glomerulonephritis (N = 6), focal gb-
merubosclerosis (N 5), minimal change glomerulopathy (N =
4) and three cases each of membranous glomerulopathy and
amyloidosis. Seven healthy volunteers who were normoten-
sive, free of known renal disease, and devoid of clinically
measurable proteinuria served as the control group.
Study protocol
Each patient and volunteer was studied in a clinical research
center after giving informed consent to a protocol that had been
approved previously by the committee for the Protection of
Human Subjects in Research at Stanford University.
Urine was voided spontaneously after a diuresis had been
established with oral water loading and in those with gross
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edema, with i.v. furosemide administration (80 to 120 mg). A
priming dose of inulin (12.5 to 25 mg/kg), paraamino-hippuric
acid (PAH 8 to 16 mg/kg), and Dextran 40 (130 mg/kg) was then
administered. Thereafter inulin and PAH were given by contin-
uous infusion to maintain plasma levels constant at approxi-
mately 20 and 1.5 mg/dliter, respectively. Sixty mm after the
priming infusion, blood was sampled for examination of hema-
tocrit, plasma oncotic pressure and plasma protein concentra-
tion. Three or four carefully timed urine collections were then
made, each of which was bracketed by a blood sample drawn
from a peripheral vein. The average inulin clearance for the
timed collection periods was taken to represent the glomerular
filtration rate (GFR). The corresponding value for the PAH
clearance was equated with renal plasma flow (RPF) after being
divided by an estimated value of the prevailing renal arteriove-
nous PAH extraction ratio (EPAH). In the case of healthy
controls EPAH was assumed to be 0.85 [12]. However, EPAH has
been shown to be moderately depressed in patients with
proteinuric glomerular diseases, particularly when GFR is
reduced [13—161. To define a representative value of EPAH in the
present study, we determine this quantity directly on a separate
occasion in five members of the experimental group. Renal and
peripheral venous blood was sampled simultaneously during a
constant infusion of PAH similar to that administered during the
clearance study. Although GFR varied widely among these five
subjects (21 to 86 mliter/minll .73m2), EPAH was distributed over
a relatively narrow range of 0.56 to 0.76, and averaged 0.68
0.04 (mean SEM). Accordingly, we assumed that EPAH during
the clearance study approximated 0.7 in the 19 nephrotic
subject in whom GFR was depressed below 100 mliter/min/
1 .73m2. In the remaining two nephrotics GFR exceeded 100
mliter/min/l.73m2 and EPAH was assumed to be 0.85, as in
normal controls.
Fractional macromolecule clearances (Om) were computed
from the first timed collection using the equation:
Om = (U/P)m/(U/P)in (1)
where (U/P)m and (U/P)1 refer to the urine to midpoint plasma
concentration ratio of the macromolecule (dextran, albumin or
IgG) and of inulin, respectively.
Upon completion of these baseline clearances, each patient
received a rapid infusion (20 mm) of 37.5 g of human albumin as
a 25% solution. Following a 40 mm period of re-equilibration, a
clearance protocol identical to that performed prior to colloid
infusion was repeated. The magnitude of the increment in
plasma volume (V) during the albumin volume—expanded state
was determined as:
= [l00/(100-Hct1] x [(Hct — Hct2)/Hct2] x 100 (2)
where Hct1 is the preinfusion hematocrit, and Hct2 the hema-
tocrit at the midpoint of the postcolloid infusion clearances.
A rather limited number of observations during the colloid
volume expanded state by earlier workers suggests that EPAH
remains unchanged in normal subjects [121 but declines by
approximately 20% below euvolemic levels in nephrotic pa-
tients [17, 18]. We confirmed this latter observation in a single
member of our experimental group in whom EPAH declined
from 0.73 at baseline to 0.64 at both 10 and 60 mm after infusion
of 37.5 g of a 25% solution of human albumin. Because of
uncertainty regarding the actual EPAH during the colloid
volume-expanded state, we calculated a likely lower and upper
bound for the value of RPF in our nephrotic subjects following
albumin infusion. The lower bound was calculated using the
same estimates of EPAH as described above for euvolemia
(EPAH = 0.7). The upper bound was computed by assuming
EPAH = 0.55.
Plasma and urinary concentrations of the exogenous clear-
ance markers in all subjects and of the endogenous proteins,
albumin and IgG in the nephrotic population were assayed using
techniques that have been described in detail previously [19]. In
the healthy controls the rate of urinary albumin excretion was
measured using a sensitive radioimmunoassay for albumin [201.
The assays for dextran and inulin concentration were per-
formed after plasma and urine samples from the first baseline
clearance (euvolemia) and the corresponding post—albumin
infusion clearance (volume-expanded) had been submitted to
gel permeation chromatography on precalibrated Sephacryl
S-300 columns. Plasma oncotic pressure was measured directly,
using a membrane osmometer [19].
Data analysis
To analyze the size—selective properties of the glomerular
capillary wall in terms of equivalent membrane—pore sizes, we
employed a heteroporous model of the glomerular capillary wall
that has been described in detail previously [11]. In this model
the major portion of the capillary wall is assumed to be
perforated by cylindrical pores of identical radius (r0). The
model assumes that there exists in addition a parallel "shunt
pathway" which does not discriminate on the basis of dextran
size, and through which passes a small fraction of the filtrate
volume. The shunt pathway is characterized by a parameter Co0
which governs (but is not equal to) the fraction of the filtrate
volume passing through this non-selective portion of the mem-
brane [11]. Specifically, co is the fraction of the filtrate volume
that would pass through the nonselective pores in the absence
of a transmembrane oncotic pressure difference. As discussed
in detail elsewhere [11], the actual fraction of the ifitrate volume
passing through these large pores is calculated to exceed o,
because fluid movement through the small pores is retarded by
the capillary oncotic pressure, whereas that through the large
pores is not. This "isoporous with shunt" model has been
shown to provide a more satisfactory representation of dextran
fractional clearances in humans than an isoporous model or
several other alternative heteroporous models [11]. According
to this model, the membrane barrier to filtration of water and
uncharged macromolecules is characterized fully by the values
of r0, con, and Kf; where Kf is the product of effective hydraulic
permeability and total glomerular capillary surface area (for two
kidneys). The approach used for calculating these intrinsic
membrane parameters separates their effects on dextran frac-
tional clearances from those of purely hemodynamic changes
[11].
All measured results are expressed as the mean 1 SEM. A
paired two—tailed Student's t test, or the Wilcoxon rank sum
test, was used to evaluate the significance of differences ob-
served between the euvolemic and volume-expanded state.
918 Shemesh el a!
Table 1. Systemic effects of albumin infusion
Healthy controls (N = 7).
Pre-
infusion
Post-
infusion P value
Hematocrit, %
plasma volume, %
Serum protein (total), mg/mIller
Serum albumin, mg/miller
Serum TgG, mg/miller
Plasma oncotic pressure,
A, mm Hg
38.1 1,0
—
65.3 1.7
38.3 1.2
ND
22.9 0.4
34.9 0.3
15 3
62.3 2.4
45.3 1.1
ND
24.3 1.1
<0.001
NS
<0.005
<0.02
Nephrotic subjects (N 21)
Pre-
infusion
Post-
infusion P value
Hematocrit, %
plasma volume, %
Serum protein, mg/muter
Serum albumin, mg/miller
Serum IgG, mg/miller
Plasma oncotic pressure,
mm Hg
35.2 1.9
—
53.7 2.2
21.4 2.2
6.3 0.8
15.2 1.0
29.8 1.6
30 6
49.5 2.7
26.1 2.1
5.0 0.7
16.8 1.2
<0.001
<0.05
<0.001
<0.001
<0.05
Abbreviation: ND, not done.
Results
Systemic effects of colloid volume expansion
Systemic effects of hyperoncotic albumin infusion are sum-
marized in Table 1. The hematocrit in both healthy controls and
nephrotic subjects was uniformly and significantly lowered.
From equation two we calculate that plasma volume was
expanded by 15 3% and 30 6%, respectively. Serum total
protein concentration also declined moderately in both groups
in the volume expanded state. This is exemplified by a 21%
lowering of mean serum IgG concentration in nephrotic sub-
jects, from 6.3 0.8 in euvolemia to 5.0 0.7 mglmliter during
hypervolemia (P < 0.001). Despite the hemodilution, however,
the hyperoncotic albumin infusion resulted in a persistent and
highly significant elevation of serum albumin concentration in
healthy controls, 38.3 1.2 to 45.3 1.1 mg/mliter (P < 0.005).
The corresponding elevation of the serum albumin level in
nephrotic subjects was from 21.4 2.2 to 26.1 2.1 mg/muter
(P < 0.001). Thus, notwithstanding the tendency to hypopro-
teinemia during hypervolemia, the mean plasma oncotic pres-
sure was increased one hour following hyperoncotic albumin
infusion by 1.4 and 1.6 mm Hg in healthy controls and nephrotic
subjects, respectively (Table 1). Mean arterial pressure (calcu-
lated as diastolic pressure plus one—third of the pulse pressure)
was substantially higher in nephrotic subjects than in healthy
controls, 102 3 vs. 85 4 mm Hg, respectively. However, in
neither group was arterial pressure altered by the albumin
infusion.
Renal effects of colloid volume expansion
As shown in Table 2, renal plasma flow in healthy controls
increased substantially above euvolemic levels during the vol-
ume expanded state, 574 57 to 777 110 mliter/minll.73 m2,
respectively (P < 0.02). Notwithstanding the increased renal
perfusion, GFR remained constant at 108 4 mliter/minll.73
m2 during euvolemia and hypervolemia. The excretion rate of
immunoassayable albumin also failed to increase following
albumin infusion.
The mean glomerular filtration rate in nephrotic subjects was
reduced by 54% below that in healthy controls, however, the
GFR was uninfluenced by albumin infusion and remained
constant. The urinary PAH clearance also remained constant.
As stated earlier, infusion of hyperoncotic albumin has been
reported to lower the extraction of PAH in nephrotic subjects
[17, 18], a finding that we confirmed in a single member of the
experimental group. The effects of this maneuver on RPF in the
nephrotic population of the present study depend therefore
upon the extent to which EPAH was depressed. Constancy of
EPAR (a worst case assumption) would yield an unchanging RPF
during hypervolemia, 602 68 vs. 568 64 mliter/min/l .73 m
in euvolemia. If, on the other hand, EPAH declined by 20% in
each patient as reported by Carghill [17] and by Michie et al
[18], then the increment in RPF in the nephrotic population
following albumin infusion would have been similar to that
observed in healthy controls, 41 vs. 36%, respectively (Table
2). It is noteworthy that despite the profound reduction of mean
GFR observed in the nephrotic population, the estimated value
of RPF in euvolemia was almost identical to that in healthy
controls (Table 2). Indeed, the initial mean filtration fraction in
nephrotic subjects was only 45% of that in healthy controls,
0,09 0.008 vs. 0.20 0.01, respectively.
In contrast to healthy controls, and in keeping with earlier
reports [1—3], hyperoncotic albumin infusion was followed by a
marked increase in urinary protein excretion in nephrotic
subjects. There was an approximately twofold increase in
urinary albumin excretion from 6513 958 to 13928 2028
gImin (P < 0.001). Urinary IgG concentration was below the
lowest standard of our assay (20 g/mliter) in six nephrotic
patients but was easily measurable in the remainder. Despite a
significant decrease in serum IgG concentration (Table 1), the
rate of urinary IgG excretion in the 15 latter nephrotic patients
increased from a euvolemic level of 680 148 to 855 178
g/min during hypervolemia (P < 0.05). The fraction of filtered
protein that is reabsorbed by endocytotic uptake into proximal
tubular cells in nephrotic animals has been shown to be minor
or negligible [8]. If this is true also of nephrotic man, then the
fractional clearance of each test protein (relative to
freely—filtered inulin) should approach its glomerular sieving
coefficient. For albumin, the fractional clearance increased
from 1.31 0.43 x 10-2 in euvolemia to 1.93 0.62 X 10-2 in
the volume—expanded state, an increase of 47% (P < 0.01). The
corresponding increase in the fractional clearance of IgG in the
15 subjects in whom this quantity could be determined was from
1.01 0.61 x 10.2 to 1.67 1.04 )< l02 an increment of 65%
(P < 0.005).
The fractional dextran clearance profile in each group was
markedly altered by albumin infusion. The findings are summa-
rized in Table 3 and illustrated in Figures 1 and 2. In keeping
with the known effects of increased RPF on the passage of
relatively permeant dextrans across the normal glomerular
capillary wall, the fractional clearances of dextrans in the 30 to
50 A radius interval in the healthy controls were significantly
lowered below euvolemic levels in the volume—expanded state
[10]. No such effect was evident on large, near—impermeant
dextrants of radius above 50 A however (Fig. 1). The alteration
Healthy controls
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Table 2. Renal effects of colloid volume expansion
Pre- infusion Post- infusion P value
NSGFR, mliter/min/1.73 m2 108 4 108 4
RPF, mliter/min/1.73 m2 574 57 777 110 <0.02
1JMb V, /.Lg/min 12.5 3.6 8.6 2.0 NS
Nephrotic subjects
Pre- infusion Post- infusion P value
NSGFR, mliter/min/1.73 m2 50 7 50 7
RPF, mliter/min/1.73 m2* 568 64 602 68 — 800 94
UaIb V, ug/min 6513 958 13928 2028 <0.001
U V, pg/mint 680 148 855 178
9aib x 10 1310 425 1926 622
<0.05
<0.01
x i0t 1010 605 1668 1042 <0.005
Symbols are: , Post—infusion RPF is expressed as a range; I'N = 15; UV, urinary excretion rate; 0, fractional clearance.
Table 3. Fractional dextran clearances
Molecular radius (A)
28 30 32 34 36 38 40 42 44 46 48 50 52 54 56 58
Healthy controls
Pre-infusion
Mean 0.875 0.707 0.553 0.409 0.307 0.242 0.176 0.122 0.087 0.058 0.038 0.025 0.016 0.010 0.0067 0.0044
SEM 0.066 0,046 0.037 0.023 0.015 0.012 0.010 0.006 0.006 0.005 0.004 0.003 0.002 0.002 0.001 0.001
Post-infusion
Mean 0.586 0.429 0.360 0.290 0.220 0.164 0.118 0.086 0.061 0.043 0.030 0.021 0.014 0.010 0.0071 0.0054
SEM 0.074 0.040 0.022 0.021 0.018 0.014 0.010 0.008 0.006 0.005 0.004 0.003 0.002 0.002 0.001 0.001
P value <0.025 <0.01 <0.01 <0.025 <0.025 <0.005<0.001 <0.001 <0.001 <0.005 <0.01 <0.05 NS NS NS NS
Nephrotc subjects
Pre-infusion
Mean 0.414 0.326 0.254 0.194 0.146 0.109 0.081 0.061 0.045 0.034 0.025 0.020 0.016 0.013 0.011 0.009
SEM 0.024 0.020 0.016 0.013 0.010 0.007 0.006 0.005 0.004 0.003 0.003 0.002 0.002 0.002 0.001 0.001
Post-infusion
Mean 0.406 0.321 0.250 0.195 0.153 0.118 0.092 0.072 0.055 0.042 0.033 0.027 0,022 0.018 0.016 0.015
SEM 0.022 0.019 0.014 0.011 0.009 0.008 0.006 0.005 0.004 0.004 0.003 0.003 0.002 0.002 0.002
P value NS NS NS NS NS NS <0.025 <0.01 <0.005 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001
0.002
<0.001
by hypervolemia of the configuration of the dextran fractional
clearance profile in nephrotic subjects differed markedly from
that in healthy controls (Fig. 2). In this case, there was a
striking and selective enhancement of the fractional clearance
of large dextrans (radius  40 A) following albumin infusion,
with the difference between euvolemia and hypervolemia be-
coming magnified with increasing size of the probe dextran
molecule. For the largest dextran examined (radius = 58 A),
fractional clearance increased by 66%, an increment similar to
that observed for the fractional clearances of albumin (+47%)
and IgG (+ 65%) in the volume—expanded state.
Analysis of membrane parameters
Values of membrane parameters calculated for the glomeru-
lar capillary wall from the mean fractional dextran clearances
provided in Table 3 are shown in Table 4. In making these
calculations a value of transmembrane hydraulic pressure dif-
ference (P) similar to that observed in various mammalian
species, or 35 mm Hg, was assumed to be representative of
pre-infusion conditions in both populations, while zP was
assumed either to remain the same or to increase slightly in
parallel with afferent oncotic pressure, ITA (to 37 mm Hg)
following colloid volume expansion. The latter assumption is
more consistent with EP measurements in experimental animals
following hyperoncotic albumin infusion [4-7]. It can be seen
that in healthy controls there is a tendency toward a slight
decrease in Kf and r0 following albumin infusion. This trend is
little affected by whether P remains constant or increases
slightly in the volume—expanded state. According to this repre-
sentation of the glomerular capillary wall, there also exists in
healthy controls a non-discriminatory shunt pathway in the
membrane through which passes a minor fraction of filtrate
volume. The prominence of this pathway is reflected by the
parameter to0, which in euvolemic controls was 0.0016. Follow-
ing albumin infusion there is an increase in this shunt parameter
to between 0.0027 and 0.0031, depending on whether or not the
increase in plasma flow is accompanied also by an increase in
P. In light of the unchanging and trace quantities of albumin
excreted in urine, it appears that this shunt pathway, while
non-discriminatory to dextrans of radius up to 58 A, continues
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Fig. 1. Fractional dextran clearances in healthy controls are plotted as
a function of effective dextran radius, before (0) and after (•) albumin
infusion. Symbols are: tP < 0,05; ** < 0.005.
26 30 34 38 42 46 50 54 58
Effective molecular radius iAi
Fig. 2. Fractional dextran clearances vs. dextran radius in nephrotic
subjects before (0) and after (•) albumin infusion. Corresponding
fractional clearaoces of albumin and IgO are depicted by open (El) and
closed squares (•), respectively. Symbols are: *P < 0.05; t5F < 0.001;
DO, euvolemia; •, hypervolemia.
Symbols are: *examines the effects of a 2 mm Hg rise in AP
post-albumin infusion; tassumes that PAH extraction declines from 0.7
to 0.55 post-albumin infusion.
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Table 4. Membrane parameters.
to restrict efficiently the transglomerular passage of proteins.
Alternately, any increase in the filtered albumin load through
the enlarged shunt following albumin infusion might not mani-
fest as an increase in albuminuria because of enhanced proximal
tubular reabsorption of filtered albumin.
The membrane parameters of the nephrotic glomerular cap-
illary wall differ markedly from those in healthy controls. K is
about five times lower, while i-0 is decresed by 4 to 5 A.
.
Moreover, neither of these parameters are altered by albumin
infusion irrespective of whether or not EPAH declined and/or P
RPF AP K
mliterl,nin nun Hg mliterl(min'mm Hg) A Wa
—— —
Euvolemia 542 35 15.6 57.6 0.0016
Hypervolemia 777 35 13.9 55.3 0.0027
Hypervolemia 777 3D' 10.9 55.6 0.0031
increased in the volume—expanded state. The nephrotic glomer- Nephrotic subjects
ular capillary wall also differs from that in healthy controls in
that massive proteinuria is associated with an increase in the
non-discnminatory shunt pathway such that the value of to 15
sixfold greater, 0.0093 vs. 0.0016, respectively. By far the
.tmia
Hypervolemia 602 37* 2.6 53.1 0.0142
Hypervolemia 800t 35 2.9 53.1 0.0138
largest change in nephrotic subjects following albumin infusion
was a considerable increase in the participation in the filtration
process of the non-discriminatory shunt pathway in the mem-
Hypervolemia 800t 37* 2.6 53.2 0.0145
brane. Thus, to0 increased by approximately 50% from 0.0093 to
between 0.0135 and 0.0145, depending upon whether RPF and
AP increased along with plasma volume following albumin
infusion. 1.8 to 8.8 1.2 muter (mm mm Hg). Pore radius r0
When the fractional dextran clearances of each individual decreased in parallel from 57.6 0.4 to 55.9 0.6 A, while to0
control and nephrotic subject were subjected to analysis in the increased from 0.00 13 0.0003 to 0.0030 0.006. Each change
manner depicted for the group data in Table 4, remarkably was significant at the P C 0.02 level. In contrast, colloid volume
similar results are obtained. When P is assumed to have expansion did not alter Kt or r0 significantly in nephrotic
increased by 2 mm Hg during hypervolemia in healthy controls, subjects. Assuming that EPAH declined to 0.55 while AP in-
Kç was found to decrease from an initial euvolemic value of 16.2 creased to 37 mm Hg during hypervolemia, the computed
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values of Kf and r0 were 2.8 0.5 and 52.7 0.6 compared
respectively to 3.8 0.9 mliter/(min mm Hg) and 52.3 0.5 A
in euvolemia. w0, however, almost doubled from 0.0079
0.0013 in euvolemia to 0.0146 0.0019 during hypervolemia (P
<0.0001). Thus, whether calculated from group or individual
fractional dextran clearance profiles, there exists a substantial
shunt pathway in the glomerular capillary wall of nephrotic
subjects which is enlarged further by colloid volume expansion.
That the fraction of filtrate volume permeating the shunt path-
way in nephrotic subjects in protein-rich is suggested by the
parallel increase in the fractional clearance of test proteins and
of the largest dextrans examined (Figure 2).
Discussion
More than 40 years have elapsed since colloid solutions were
introduced into clinical medicine for use as intravascular
volume—expanders. Soon after, it was observed that infusion of
hyperoncotic solutions of either albumin [1—3] or dextran [21]
magnified proteinuria in nephrotic patients. Our findings con-
firm these earlier observations (Table 2). In addition, we have
demonstrated that enhanced proteinuria is accompanied by an
increase in the transglomerular passage of large, near—imperme-
ant dextrans in the albumin—infused nephrotic subject. This
latter finding points strongly to a defect in glomerular
size—selectivity as a major determinant of the increasing pro-
teinuria[ll, 19].
In attempting to describe the alteration in glomerular barrier
size—selectivity induced by hyperoncotic albumin infusion, we
have applied the observed fractional dextran clearances to a
theoretical model of hindered solute transport through a
heteroporous membrane. As reviewed recently, glomerular
size—selectivity has been represented in many previous studies
by idealizing the filtration barrier as an isoporous membrane,
one containing cylindrical pores of uniform size [221. That an
isoporous model is incompatible with the glomerular capillary
wall of nephrotic patients however, is readily appreciated by a
comparison of the fractional dextran clearances of the nephrotic
subjects of the present study with those of healthy controls
(Fig. 3). No single population of glomerular pores of uniform
size can simultaneously account for the reduced transglomeru-
lar transport of smaller dextrans (radius <50 A) but enhanced
transport of larger dextrans (radius > 50 A) illustrated for
nephrotic subjects relative to healthy controls in Figure 3. We
have accordingly used a recently described heteroporous ide-
alization of the glomerular capillary wall [11]. This current
model assumes that the major portion of the glomerular capil-
lary wall functions as an isoporous membrane, while a minor
fraction of filtrate volume passes through a second population
of pores, relatively few in number but of sufficiently large size
that they fail to restrict the passage of dextrans of up to 58 A
radius. The current model also includes mass balance relations
that predict variations in solute concentrations and fluxes along
the length of the glomerular capillary. In this way it becomes
possible to isolate the influence of hemodynamic factors on
fractional dextran clearances from that due to the intrinsic
selectivity of the glomerular capillary wall [11, 22].
The utility of this approach is depicted by considering the
fractional dextran clearances in Figures 1 and 2. Depression of
transglomerular transport of dextrans of broad size distribution
following albumin infusion in healthy subjects suggests that the
entire glomerular capillary wall has become more restrictive
(Fig. 1). An opposite effect of albumin infusion to enhance
transglomerular transport of dextrans of broad size distribution
in nephrotic subjects suggests that in this instance the glomer-
ular capillary wall has become less restrictive (Fig. 2). The
calculated membrane parameters indicate, however, that when
the effect of glomerular pressures and perfusion rate on
transmembrane driving forces for dextran movement are taken
into account, the intrinsic properties of the glomerular capillary
wall are changed in similar fashion in the two populations. We
conclude that for the normal individuals, the fractional clear-
ances of the largest dextrans did not change significantly
because the tendency for high plasma flows to decrease frac-
tional clearances was offset by the emergence of more large
pores. For the nephrotic subjects, the elevation of plasma flow
rate was insufficient to nullify the effects on large dextrans of an
augmented shunt pathway, so that their fractional clearances
increased. Thus, it is only through the calculation of
membrane—pore parameters, and not simply by inspection of
the sieving curves, that the membrane changes associated with
albumin infusion are revealed to be qualitatively similar in
normal and nephrotic subjects. The most marked alteration in
each instance is an augmentation of the shunt pathway, the
non-discriminatory subset of large pores of the glomerular
membrane.
From the difference in membrane—pore structure between
normal and nephrotic subjects in euvolemia, we infer that
massive proteinuria is a consequence, at least in part, of a large
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Fig. 3. The fractional dextran clearance profile of euvolemic nephrotic
subjects (•) is compared to that of euvolemic healthy controls (0).
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increase in the fraction of macromolecule—rich filtrate volume
that passes through relatively large and non-selective pores
[11]. Moreover, increased urinary protein leakage following
albumin infusion is associated with a further increase by —50%
in the fraction of filtrate volume permeating the non-selective
shunt pathway through large pores. A parallel increase of
similar magnitude in the fractional clearance of the largest
dextran fraction examined (58 A), of albumin and of IgG, is
consistent with a progressive loss of size—selectivity by the
nephrotic glomerular capillary wall in the colloid, volume—ex-
panded state.
Why the much smaller shunt pathway in the healthy glomer-
ular capillary wall of control subjects, and its enlargement by
colloid volume expansion, is not accompanied by significant
proteinuria cannot be determined from the present data. Con-
ceivably any increase in the load of protein filtered through the
shunt pathway in the volume—expanded state might undergo
tubular reabsorption. Alternately, the larger pores of the shunt
pathway in normal controls may differ from those in the
nephrotic glomerular capillary wall by exhibiting a greater
degree of charge and shape—selectivity [23, 241. The precise
mechanism by which some portion of a porous membrane may
readily pass large dextrans, yet severely restrict proteins of
equivalent size, remains to be determined.
When taken together with more direct measurements in
experimental animals, our observations suggest that altered
glomerular capillary hemodynamics underlie the alteration in
membrane—pore structure that attends colloid volume expan-
sion. Direct examination of surface glomeruli has revealed
elevation of plasma flow, n and P in the normal
Munich—Wistar rat during infusion of hyperoncotic albumin
[4—61. This maneuver clearly also elevated RPF and increased
ITA in the healthy control subjects of the present study (Tables
1 and 2). As discussed previously, others have shown, and we
have confirmed, that renal PAH extraction in nephrotic subjects
declines following albumin infusion [17, 181. It is possible,
therefore, that RPF increased substantially in the nephrotic
subjects of the present study notwithstanding constancy of the
urinary PAH clearance (Table 2). The transmembrane hydraulic
pressure difference, P cannot be measured in man. From the
findings in the rat, however, it seems that this determinant of
GFR rises in proportion to and thereby offsets the increase in
IrA induced by the hyperoncotic albumin infusion. Since ITA
increased post—infusion in nephrotic subjects, it seems not
unreasonable to suppose that, as in the rat, zP increased in
parallel. It is important to emphasize moreover, that elevation
of glomerular capillary hydraulic pressure, and hence AP, has
been observed as an adaptive response to all proteinuric
glomerular injuries in the rat that have been studied to date with
micropuneture techniques [9, 25—281. On occasion adaptive
glomerular hyperfusion has also been documented [9, 28]. Thus
any increase in glomerular perfusion rate and pressure induced
by colloid volume expansion in the nephrotic subjects of the
present study may have occurred in a setting of pre-existing
glomerular capillary hyperemia and hypertension.
A growing body of evidence points to elevated glomerular
perfusion pressure as a potential modulator of glomerular
barrier function. In the rat, infusion of subpressor doses of
angiotensin II has been shown to elevate glomerular capillary
hydraulic pressure, and hence iSP, and also to induce substan-
tial proteinuria [29—31]. An even more striking effect to mas-
sively enhance pre-existing proteinuria has been observed when
angiotensin II was infused into rats with aminonucleo-
side—induced nephropathy [32]. Pessina et al used neutral
polyvinylpyrrolidones of broad size distribution to study the
effect of angiotensin II infusion on glomerular barrier function
in the normal rat [311. They demonstrated selective enhance-
ment in transport of large (> 50 A radius) polyvinylpyrrolidones
following infusion of angiotensin II. This latter finding is re-
markably similar to the altered size—selectivity induced by
albumin infusion in the nephrotic subjects of the present study
(Fig. 2). We measured plasma renin activity in seven members
of the experimental nephrotic population. In keeping with the
known effects of volume expansion, it declined from 2.0 0.7
during euvolemia to 1.1 0.4 ng/mliter/hr in the wake of
albumin infusion (P C 0.05). Presumably there was a concom-
mitant decrease in plasma angiotensin II concentration. Thus
irrespective of whether or not glomerular capillary hyperten-
sion was responsible for altered glomerular permselectivity
following colloid volume expansion, angiotensin II per se is
unlikely to have been implicated.
More pertinent perhaps to the present study are the findings
of Tiggeler, Hulme, and Hijdeveld 133]. They were able to
reduce the rate of urinary protein excretion in nephrotic sub-
jects by administration of the cyclo-oxygenase inhibitor, indo-
methacin. Reduced proteinuria was accompanied by a selective
lowering from the untreated state of the fractional clearances of
large (> 50 A radius) but not small polyvinylpyrrolidone mole-
cules. Although not measured in the foregoing study, indometh-
acm administration is likely to have increased renal vascular
resistance [34]. Thus, when taken together with the present
findings, a discernible relationship becomes manifest in ne-
phrotic subjects between the magnitude of glomerular perfusion
rate (and/or pressure) on the one hand, and that of a defect in
the size—selective barrier and proteinuria on the other. Such a
relationship may provide a hemodynamic basis for some of the
spontaneous fluctuations in the magnitude of proteinuria that
are frequently observed in patients with the nephrotic syndrome.
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